$HELP News

Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade)

Helus Pharma CEO Michael Cola Stepping Down, Effective Immediately; Executive Chairman Eric So Appointed Interim CEO

TD Cowen Initiates Coverage On Helus Pharma with Buy Rating, Announces Price Target of $8

Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder - Slideshow

Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript

HC Wainwright & Co. Maintains Buy on Helus Pharma, Raises Price Target to $95

HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience

Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise

Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth Drivers

Helus Pharma shares are trading higher after the company announced publication in Nature Medicine of results from a Phase 2a clinical trial evaluating SPL026, in major depressive disorder.

Helus Pharma shares are trading higher after the company announced publication in Nature Medicine of results from a Phase 2a clinical trial evaluating SPL026, in major depressive disorder.

Helus Pharma Announces Publication In Nature Medicine Of Results From Phase 2a Randomized, Placebo-Controlled Clinical Trial Evaluating SPL026, In Participants With Moderate-To-Severe MDD

Here's Why We're Watching Cybin's (NASDAQ:HELP) Cash Burn Situation

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Helus Pharma Q3 EPS $(1.00) Misses $(0.80) Estimate

Helus PharmaTM Appoints Michael Cola CEO, Effective Immediately

Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Cybin (NYSEAM:CYBN) Valuation Check After Strategic Move to Nasdaq Global Market Listing

Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges